Fusheng Pharmaceutical (300497.SZ) released its first-quarter performance with a net profit attributable to the parent company of 2.2388 million yuan, an increase of 52.46%.

Zhito Financial News App, Fuxiang Pharmaceutical (300497.SZ) released its first quarter report for 2025, with the company's operating income at 234 million yuan, a decrease of 31.35% compared to the same period last year. Net profit attributable to the shareholders of the listed company was 2.2388 million yuan, an increase of 52.46% compared to the same period last year. Net loss attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 22.5996 million yuan, an increase of 125.95% compared to the same period last year. Basic earnings per share were 0.004 yuan.